title: Evaluation of the relationship between polymorphisms in CYP2C19 and the pharmacokinetics of omeprazole, pantoprazole and rabeprazole.
abstract: OBJECTIVE
  To evaluate the possible association between polymorphisms in CYP2C19 and the pharmacokinetics of omeprazole, rabeprazole and pantoprazole.
  
  
  METHODS
  151 healthy volunteers were evaluated for polymorphisms in the CYP2C19 gene using real-time polymerase chain reaction. Plasma concentrations were measured using high-performance liquid chromatography coupled to mass spectrometry.
  
  
  RESULTS
  Carriers of the *2 allele displayed poor metabolism for all the PPIs studied (around 50% decrease in clearance). Subjects with the *17 allele showed a light increase in clearance compared with *1/*1 (not significant).
  
  
  CONCLUSIONS
  CYP2C19*2 is associated with decreased clearance of all the PPIs, that could be associated with higher drug efficacy. CYP2C19*17 could increase clearance of these drugs, although the effect seems small.
authors.affiliation: Service of Clinical Pharmacology, Hospital Universitario de la Princesa, Instituto Teófilo Hernando, Instituto de Investigación Sanitaria Princesa (IP), Diego de León 62, 28006 Madrid, Spain.
authors.forename: Manuel
authors.initials: M
authors.lastname: Román
authors.forename: Dolores
authors.initials: D
authors.lastname: Ochoa
authors.forename: Sergio Daniel
authors.initials: SD
authors.lastname: Sánchez-Rojas
authors.forename: Maria
authors.initials: M
authors.lastname: Talegón
authors.forename: Rocio
authors.initials: R
authors.lastname: Prieto-Pérez
authors.forename: Ângela
authors.initials: Â
authors.lastname: Rivas
authors.forename: Francisco
authors.initials: F
authors.lastname: Abad-Santos
authors.forename: Teresa
authors.initials: T
authors.lastname: Cabaleiro
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000008:administration & dosage / Q000493:pharmacokinetics*; D000328:Adult; D065731:Cytochrome P-450 CYP2C19 / Q000235:genetics*; D005260:Female; D056726:Genetic Association Studies; D005838:Genotype; D006801:Humans; D008658:Inactivation, Metabolic / Q000235:genetics; D008297:Male; D009853:Omeprazole / Q000008:administration & dosage / Q000493:pharmacokinetics*; D000077402:Pantoprazole; D011110:Polymorphism, Genetic; D064750:Rabeprazole / Q000008:administration & dosage / Q000493:pharmacokinetics*
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D064750:Rabeprazole; D000077402:Pantoprazole; D065731:Cytochrome P-450 CYP2C19; D009853:Omeprazole
keywords: CYP2C19; pharmacogenetics; pharmacokinetics; proton-pump inhibitors